Your browser doesn't support javascript.
loading
Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.
Rhodes, Sophie J; Knight, Gwenan M; Fielding, Katherine; Scriba, Thomas J; Pathan, Ansar A; McShane, Helen; Fletcher, Helen; White, Richard G.
  • Rhodes SJ; TB Modelling Group, CMMID, TB Centre, London School of Hygiene and Tropical Medicine, UK. Electronic address: sophie.rhodes@lshtm.ac.uk.
  • Knight GM; National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, UK.
  • Fielding K; Infectious Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, UK.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Pathan AA; College of Health and Life Sciences, Department of Life Sciences, Brunel University, UK.
  • McShane H; The Jenner Institute, UK University, UK.
  • Fletcher H; Immunology and Infection Department, London School of Hygiene and Tropical Medicine, UK.
  • White RG; TB Modelling Group, CMMID, TB Centre, London School of Hygiene and Tropical Medicine, UK.
Tuberculosis (Edinb) ; 96: 37-43, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26786653
ABSTRACT

INTRODUCTION:

A more effective tuberculosis (TB) vaccine is needed to eliminate TB disease. Many new vaccine candidates enhance the immunogenicity of the existing vaccine, Bacillus Calmette-Guérin (BCG). Understanding BCG induced immune variation is key to developing a new vaccine.

AIMS:

We aimed to establish if individual-level covariates were associated with cell-mediated immune response (interferon gamma (IFN-γ)) at vaccine trial enrolment (baseline) in a long-term retrospective analysis (LTR) and after BCG vaccination in a short-term prospective analysis (STP).

METHODS:

Four covariates were analysed gender, country, BCG vaccination history and monocyte/lymphocyte cell count ratio. Univariable and multivariable linear regression were conducted on IFN-γ response at baseline for LTR, and area under the curve (AUC), 24 week and peak IFN-γ response for STP.

RESULTS:

Previous BCG vaccination was strongly associated with higher IFN-γ response at baseline (LTR analysis) (p-values < 0.05). Being male showed a weak association with higher baseline response (p-value = 0.1). BCG revaccination was strongly associated with a larger response increase than primary-vaccination (AUC & peak p-values < 0.01), but did not differ at 24 weeks (STP analysis). All other covariates were non-significant (p-values > 0.1).

CONCLUSION:

This analysis suggests that previous BCG vaccination and gender are associated with durable IFN-γ responses. Vaccine trials may need to stratify by BCG vaccination history and gender.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacuna BCG / Interferón gamma / Vacunación / Inmunidad Celular / Mycobacterium tuberculosis Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacuna BCG / Interferón gamma / Vacunación / Inmunidad Celular / Mycobacterium tuberculosis Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article